A worldwide overview for hexavalent vaccines and a glimpse into Turkiye's perspective

The surge in recommended vaccinations for child's has spurred the development of combination vaccines, notably hexavalent vaccines, which provide multiple immunizations in a single dose. These vaccines offer various advantages, such as streamlining vaccination schedules, minimizing injection-re...

Full description

Saved in:
Bibliographic Details
Published inHuman vaccines & immunotherapeutics Vol. 20; no. 1; p. 2345493
Main Authors Özen, Metehan, Ünüvar, Emin, Yıldırım, Abdurrahman, Akman, Hakkı, Mevlitoğlu, Süleyman, Pehlivan, Tamer
Format Journal Article
LanguageEnglish
Published United States Taylor & Francis Group 31.12.2024
Subjects
childhood immunization
combination vaccines
Hexavalant vaccines
Humans
Immunization Programs
Immunization Schedule
immunogenicity
Turkey
Vaccination
Vaccination Coverage
Vaccination Hesitancy - statistics & numerical data
vaccination strategies
vaccine safety
Vaccine-Preventable Diseases - prevention & control
Vaccines, Combined - administration & dosage
Vaccines, Combined - immunology
Turkey
vaccine safety
vaccination strategies
combination vaccines
Hexavalant vaccines
childhood immunization
immunogenicity
Online AccessGet full text

Cover

Abstract The surge in recommended vaccinations for child's has spurred the development of combination vaccines, notably hexavalent vaccines, which provide multiple immunizations in a single dose. These vaccines offer various advantages, such as streamlining vaccination schedules, minimizing injection-related pain and exposure to preservatives, expanding vaccine coverage, and reducing administration costs. However, the intricate and expensive development of these vaccines presents substantial challenges, requiring increased investment and healthcare provider education to optimize their utilization and sustain high vaccination rates. Turkey, known for its robust vaccine coverage, strategic geographic location, and the influx of refugees, is at a critical juncture for integrating hexavalent vaccines into national programs. This transition is especially relevant given the rising vaccine hesitancy and the potential resurgence of vaccine-preventable diseases. This review assesses the deployment of hexavalent vaccines, examining their benefits and challenges through clinical trials and global experiences, with a specific emphasis on Turkiye's public health context.
AbstractList The surge in recommended vaccinations for child's has spurred the development of combination vaccines, notably hexavalent vaccines, which provide multiple immunizations in a single dose. These vaccines offer various advantages, such as streamlining vaccination schedules, minimizing injection-related pain and exposure to preservatives, expanding vaccine coverage, and reducing administration costs. However, the intricate and expensive development of these vaccines presents substantial challenges, requiring increased investment and healthcare provider education to optimize their utilization and sustain high vaccination rates. Turkey, known for its robust vaccine coverage, strategic geographic location, and the influx of refugees, is at a critical juncture for integrating hexavalent vaccines into national programs. This transition is especially relevant given the rising vaccine hesitancy and the potential resurgence of vaccine-preventable diseases. This review assesses the deployment of hexavalent vaccines, examining their benefits and challenges through clinical trials and global experiences, with a specific emphasis on Turkiye's public health context.
ABSTRACTThe surge in recommended vaccinations for child’s has spurred the development of combination vaccines, notably hexavalent vaccines, which provide multiple immunizations in a single dose. These vaccines offer various advantages, such as streamlining vaccination schedules, minimizing injection-related pain and exposure to preservatives, expanding vaccine coverage, and reducing administration costs. However, the intricate and expensive development of these vaccines presents substantial challenges, requiring increased investment and healthcare provider education to optimize their utilization and sustain high vaccination rates. Turkey, known for its robust vaccine coverage, strategic geographic location, and the influx of refugees, is at a critical juncture for integrating hexavalent vaccines into national programs. This transition is especially relevant given the rising vaccine hesitancy and the potential resurgence of vaccine-preventable diseases. This review assesses the deployment of hexavalent vaccines, examining their benefits and challenges through clinical trials and global experiences, with a specific emphasis on Turkiye’s public health context.
The surge in recommended vaccinations for child's has spurred the development of combination vaccines, notably hexavalent vaccines, which provide multiple immunizations in a single dose. These vaccines offer various advantages, such as streamlining vaccination schedules, minimizing injection-related pain and exposure to preservatives, expanding vaccine coverage, and reducing administration costs. However, the intricate and expensive development of these vaccines presents substantial challenges, requiring increased investment and healthcare provider education to optimize their utilization and sustain high vaccination rates. Turkey, known for its robust vaccine coverage, strategic geographic location, and the influx of refugees, is at a critical juncture for integrating hexavalent vaccines into national programs. This transition is especially relevant given the rising vaccine hesitancy and the potential resurgence of vaccine-preventable diseases. This review assesses the deployment of hexavalent vaccines, examining their benefits and challenges through clinical trials and global experiences, with a specific emphasis on Turkiye's public health context.The surge in recommended vaccinations for child's has spurred the development of combination vaccines, notably hexavalent vaccines, which provide multiple immunizations in a single dose. These vaccines offer various advantages, such as streamlining vaccination schedules, minimizing injection-related pain and exposure to preservatives, expanding vaccine coverage, and reducing administration costs. However, the intricate and expensive development of these vaccines presents substantial challenges, requiring increased investment and healthcare provider education to optimize their utilization and sustain high vaccination rates. Turkey, known for its robust vaccine coverage, strategic geographic location, and the influx of refugees, is at a critical juncture for integrating hexavalent vaccines into national programs. This transition is especially relevant given the rising vaccine hesitancy and the potential resurgence of vaccine-preventable diseases. This review assesses the deployment of hexavalent vaccines, examining their benefits and challenges through clinical trials and global experiences, with a specific emphasis on Turkiye's public health context.
Author Mevlitoğlu, Süleyman
Ünüvar, Emin
Pehlivan, Tamer
Akman, Hakkı
Özen, Metehan
Yıldırım, Abdurrahman
Author_xml – sequence: 1
  givenname: Metehan
  orcidid: 0000-0003-4088-3103
  surname: Özen
  fullname: Özen, Metehan
  organization: School of Medicine, Department of Pediatric Infectious Disease, Acıbadem University, İstanbul, Turkiye
– sequence: 2
  givenname: Emin
  orcidid: 0000-0003-2685-6483
  surname: Ünüvar
  fullname: Ünüvar, Emin
  organization: School of Medicine, Department of Pediatric Disease, Istanbul University, Istanbul, Turkiye
– sequence: 3
  givenname: Abdurrahman
  surname: Yıldırım
  fullname: Yıldırım, Abdurrahman
  organization: Pediatric Disease, Dr Abdurrahman Yıldırım Clinic, Istanbul, Turkiye
– sequence: 4
  givenname: Hakkı
  surname: Akman
  fullname: Akman, Hakkı
  organization: Department of Pediatric Disease, Güven Hospital, Ankara, Turkiye
– sequence: 5
  givenname: Süleyman
  surname: Mevlitoğlu
  fullname: Mevlitoğlu, Süleyman
  organization: Pediatric Disease, Dolunay Children Clinic, Antalya, Turkiye
– sequence: 6
  givenname: Tamer
  surname: Pehlivan
  fullname: Pehlivan, Tamer
  organization: Public Health, Remedium Consulting Group, İzmir, Turkiye
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38780074$$D View this record in MEDLINE/PubMed
BookMark eNo9kU1PGzEQhq2KqlDgJ7TyrVyS-tvxEaHSIiH1AhI3a9aepaab9dbebMq_76YJmct86J13pHk-kpM-90jIJ86WnK3YV8GN0prrpWBCLYVUWjn5jpzt5gut1dPJseb6lFzW-sLmsLPamA_kVK7sam7VGXm8pttcurhNEWmesEwJt7TNhf7CvzBBh_1IJwgh9Vgp9JECfe7SeqhIUz9m-rApv9Mrfql0wFIHDGOa8IK8b6GreHnI5-Tx9tvDzY_F_c_vdzfX94sgLRsX0oKCplUmGi3BIDeaMS0bYOCYtoIBOKNdywS0MUJwTAQOTkkOsWGCyXNyt_eNGV78UNIayqvPkPz_QS7PHsqYQofeiMZq0eogIlfCCQgscjn_oLFW2lbPXld7r6HkPxuso1-nGrDroMe8qV4y7YS2nLtZqvfSUHKtBdvjac78DpB_A-R3gPwB0Lz3-XBi06wxHrfecMh_asyL0g
Cites_doi 10.1097/01.inf.0000222413.47344.23
10.1097/INF.0000000000001682
10.1016/j.vaccine.2006.03.032
10.26719/2018.24.5.451
10.4161/hv.28480
10.1097/INF.0000000000001358
10.1016/j.ijid.2010.12.004
10.1016/j.vaccine.2018.10.100
10.1016/j.vaccine.2015.06.030
10.4103/0974-777X.77298
10.1016/j.vaccine.2017.06.063
10.4161/hv.26269
10.31925/farmacia.2018.5.2
10.1586/erv.09.32
10.1001/archfami.3.7.610
10.1186/s12913-021-07428-7
10.1097/INF.0000000000001405
10.1016/j.vaccine.2006.09.060
10.1001/archpedi.153.12.1289
10.15585/mmwr.mm7107a2
10.1542/peds.2004-2336
10.1016/j.vaccine.2003.11.044
10.1016/j.vaccine.2016.11.053
10.1016/S0264-410X(01)00230-4
10.1080/21645515.2015.1044180
10.3906/sag-1609-62
10.1097/INF.0000000000001406
10.1016/j.vaccine.2022.12.021
10.1080/14760584.2016.1205492
10.1016/j.vaccine.2008.03.001
10.1097/01.inf.0000148923.46453.48
10.1007/s40272-019-00353-7
10.1111/j.1749-6632.1995.tb44431.x
10.1136/archdischild-2019-317707
10.1016/j.vaccine.2019.04.088
10.1016/s0264-410x(03)00420-1
10.4161/hv.29361
10.1179/oeh.2004.10.4.451
10.1016/j.vaccine.2012.07.040
10.1093/trstmh/trt039
10.1086/322575
10.4161/hv.2.6.3432
10.1016/j.vaccine.2004.06.017
10.1067/mph.2003.42
10.1097/00006454-200111001-00002
10.1016/j.vaccine.2016.05.054
10.1080/21645515.2020.1764826
10.1097/INF.0b013e318212eb80
10.1097/00006454-200209000-00014
10.1542/peds.2005-2907
10.1517/14712598.2013.774368
10.1016/j.vaccine.2017.05.062
10.15167/2421-4248/jpmh2020.61.3.1535
10.1016/j.jval.2016.09.367
10.1016/S0264-410X(98)00424-1
10.1016/j.biologicals.2017.08.008
10.1080/21645515.2016.1202388
10.1097/00006454-200111001-00006
10.1067/mpd.2000.107796
10.1007/s10198-003-0216-z
10.1016/j.vaccine.2021.08.086
10.1111/1469-0691.12444
10.4172/2157-7560.1000128
10.1016/j.healthpol.2020.11.004
10.1080/21645515.2021.1923345
10.1097/INF.0000000000002109
10.1016/j.vaccine.2023.08.046
10.21101/cejph.a5543
10.1097/INF.0000000000002231
10.1097/00006454-199405000-00012
10.1097/INF.0b013e318292f7b1
10.1016/j.ijid.2014.03.1307
10.1080/14760584.2018.1419070
10.1542/peds.2014-4102
10.1080/21645515.2019.1673119
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
DOA
DOI 10.1080/21645515.2024.2345493
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
Directory of Open Access Journals
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList MEDLINE

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2164-554X
ExternalDocumentID oai_doaj_org_article_62b752f5c2d14292ac0d13074b7737f5
10_1080_21645515_2024_2345493
38780074
Genre Research Support, Non-U.S. Gov't
Journal Article
Review
GeographicLocations Turkey
GeographicLocations_xml – name: Turkey
GroupedDBID ---
00X
0YH
30N
4.4
53G
AALUX
ABEIZ
ABUPF
ACENM
ACGFS
ADBBV
ADCVX
AECIN
AENEX
AEXWM
AGYJP
AIJEM
ALMA_UNASSIGNED_HOLDINGS
ALQZU
AOIJS
ARJSQ
BABNJ
BAWUL
BLEHA
BOHLJ
CCCUG
CGR
CUY
CVF
EBS
ECM
EIF
EMOBN
GROUPED_DOAJ
H13
KYCEM
LJTGL
M4Z
NPM
O9-
RIG
RPM
SV3
TDBHL
TFL
TFW
TTHFI
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-c370t-37a4abf46d653a6e1650053ba0a905720aa9659f02afddac902c1a9431adb0203
IEDL.DBID DOA
ISSN 2164-5515
2164-554X
IngestDate Tue Oct 22 15:03:27 EDT 2024
Thu Nov 28 02:00:36 EST 2024
Fri Dec 06 06:29:11 EST 2024
Thu Nov 28 21:20:53 EST 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords vaccine safety
vaccination strategies
combination vaccines
Hexavalant vaccines
childhood immunization
immunogenicity
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c370t-37a4abf46d653a6e1650053ba0a905720aa9659f02afddac902c1a9431adb0203
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ORCID 0000-0003-4088-3103
0000-0003-2685-6483
OpenAccessLink https://doaj.org/article/62b752f5c2d14292ac0d13074b7737f5
PMID 38780074
PQID 3059257119
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_62b752f5c2d14292ac0d13074b7737f5
proquest_miscellaneous_3059257119
crossref_primary_10_1080_21645515_2024_2345493
pubmed_primary_38780074
PublicationCentury 2000
PublicationDate 2024-12-31
PublicationDateYYYYMMDD 2024-12-31
PublicationDate_xml – month: 12
  year: 2024
  text: 2024-12-31
  day: 31
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Human vaccines & immunotherapeutics
PublicationTitleAlternate Hum Vaccin Immunother
PublicationYear 2024
Publisher Taylor & Francis Group
Publisher_xml – name: Taylor & Francis Group
References e_1_3_4_3_1
e_1_3_4_61_1
e_1_3_4_84_1
e_1_3_4_63_1
e_1_3_4_86_1
e_1_3_4_9_1
e_1_3_4_42_1
e_1_3_4_80_1
e_1_3_4_40_1
e_1_3_4_82_1
e_1_3_4_5_1
e_1_3_4_23_1
e_1_3_4_46_1
e_1_3_4_69_1
e_1_3_4_21_1
e_1_3_4_44_1
e_1_3_4_27_1
e_1_3_4_65_1
e_1_3_4_88_1
e_1_3_4_25_1
e_1_3_4_48_1
e_1_3_4_67_1
e_1_3_4_29_1
Dodd D (e_1_3_4_10_1) 2003; 9
e_1_3_4_72_1
e_1_3_4_74_1
e_1_3_4_53_1
e_1_3_4_91_1
e_1_3_4_30_1
e_1_3_4_51_1
e_1_3_4_70_1
e_1_3_4_13_1
e_1_3_4_34_1
e_1_3_4_59_1
Kurugol Z (e_1_3_4_78_1) 2009; 3
e_1_3_4_55_1
e_1_3_4_11_1
e_1_3_4_32_1
e_1_3_4_76_1
e_1_3_4_17_1
e_1_3_4_38_1
e_1_3_4_15_1
e_1_3_4_36_1
e_1_3_4_57_1
e_1_3_4_19_1
e_1_3_4_4_1
e_1_3_4_2_1
e_1_3_4_62_1
e_1_3_4_83_1
e_1_3_4_64_1
e_1_3_4_85_1
e_1_3_4_8_1
e_1_3_4_20_1
e_1_3_4_41_1
e_1_3_4_6_1
e_1_3_4_60_1
e_1_3_4_81_1
e_1_3_4_24_1
e_1_3_4_45_1
e_1_3_4_22_1
e_1_3_4_43_1
e_1_3_4_28_1
e_1_3_4_49_1
e_1_3_4_66_1
e_1_3_4_87_1
e_1_3_4_26_1
e_1_3_4_47_1
e_1_3_4_68_1
e_1_3_4_89_1
Keja K (e_1_3_4_7_1) 1988; 41
e_1_3_4_73_1
e_1_3_4_75_1
e_1_3_4_31_1
e_1_3_4_52_1
e_1_3_4_90_1
e_1_3_4_50_1
e_1_3_4_71_1
e_1_3_4_92_1
e_1_3_4_12_1
e_1_3_4_35_1
e_1_3_4_58_1
e_1_3_4_33_1
e_1_3_4_54_1
e_1_3_4_16_1
e_1_3_4_39_1
e_1_3_4_77_1
e_1_3_4_14_1
e_1_3_4_37_1
e_1_3_4_56_1
e_1_3_4_79_1
e_1_3_4_18_1
References_xml – volume: 3
  start-page: 14
  year: 2009
  ident: e_1_3_4_78_1
  article-title: Pertussis epidemiology in Turkey: are booster doses necessary?/Turkiye’de bogmaca epidemiyolojisi pekistirme asi dozlari gerekli mi?
  publication-title: J Pediatr Infect
  contributor:
    fullname: Kurugol Z
– ident: e_1_3_4_15_1
  doi: 10.1097/01.inf.0000222413.47344.23
– ident: e_1_3_4_28_1
  doi: 10.1097/INF.0000000000001682
– ident: e_1_3_4_40_1
  doi: 10.1016/j.vaccine.2006.03.032
– ident: e_1_3_4_84_1
  doi: 10.26719/2018.24.5.451
– ident: e_1_3_4_44_1
  doi: 10.4161/hv.28480
– ident: e_1_3_4_29_1
  doi: 10.1097/INF.0000000000001358
– ident: e_1_3_4_27_1
  doi: 10.1016/j.ijid.2010.12.004
– ident: e_1_3_4_57_1
  doi: 10.1016/j.vaccine.2018.10.100
– ident: e_1_3_4_8_1
  doi: 10.1016/j.vaccine.2015.06.030
– ident: e_1_3_4_2_1
  doi: 10.4103/0974-777X.77298
– ident: e_1_3_4_68_1
  doi: 10.1016/j.vaccine.2017.06.063
– ident: e_1_3_4_47_1
  doi: 10.4161/hv.26269
– ident: e_1_3_4_67_1
  doi: 10.31925/farmacia.2018.5.2
– ident: e_1_3_4_21_1
– ident: e_1_3_4_74_1
– ident: e_1_3_4_45_1
  doi: 10.1586/erv.09.32
– ident: e_1_3_4_11_1
  doi: 10.1001/archfami.3.7.610
– ident: e_1_3_4_90_1
  doi: 10.1186/s12913-021-07428-7
– ident: e_1_3_4_70_1
– ident: e_1_3_4_88_1
– ident: e_1_3_4_61_1
  doi: 10.1097/INF.0000000000001405
– ident: e_1_3_4_42_1
  doi: 10.1016/j.vaccine.2006.09.060
– ident: e_1_3_4_12_1
  doi: 10.1001/archpedi.153.12.1289
– ident: e_1_3_4_75_1
  doi: 10.15585/mmwr.mm7107a2
– ident: e_1_3_4_39_1
  doi: 10.1542/peds.2004-2336
– ident: e_1_3_4_38_1
  doi: 10.1016/j.vaccine.2003.11.044
– ident: e_1_3_4_54_1
  doi: 10.1016/j.vaccine.2016.11.053
– ident: e_1_3_4_13_1
  doi: 10.1016/S0264-410X(01)00230-4
– ident: e_1_3_4_3_1
  doi: 10.1080/21645515.2015.1044180
– ident: e_1_3_4_56_1
  doi: 10.3906/sag-1609-62
– ident: e_1_3_4_31_1
  doi: 10.1097/INF.0000000000001406
– ident: e_1_3_4_59_1
  doi: 10.1016/j.vaccine.2022.12.021
– ident: e_1_3_4_69_1
  doi: 10.1080/14760584.2016.1205492
– ident: e_1_3_4_72_1
  doi: 10.1016/j.vaccine.2008.03.001
– ident: e_1_3_4_33_1
  doi: 10.1097/01.inf.0000148923.46453.48
– ident: e_1_3_4_32_1
  doi: 10.1007/s40272-019-00353-7
– ident: e_1_3_4_6_1
  doi: 10.1111/j.1749-6632.1995.tb44431.x
– ident: e_1_3_4_73_1
  doi: 10.1136/archdischild-2019-317707
– ident: e_1_3_4_24_1
  doi: 10.1016/j.vaccine.2019.04.088
– ident: e_1_3_4_36_1
  doi: 10.1016/s0264-410x(03)00420-1
– ident: e_1_3_4_64_1
– ident: e_1_3_4_16_1
  doi: 10.4161/hv.29361
– ident: e_1_3_4_17_1
  doi: 10.1179/oeh.2004.10.4.451
– volume: 9
  start-page: S6
  year: 2003
  ident: e_1_3_4_10_1
  article-title: Benefits of combination vaccines: effective vaccination on a simplified schedule
  publication-title: Am J Manag Care
  contributor:
    fullname: Dodd D
– ident: e_1_3_4_26_1
  doi: 10.1016/j.vaccine.2012.07.040
– ident: e_1_3_4_14_1
  doi: 10.1093/trstmh/trt039
– ident: e_1_3_4_23_1
  doi: 10.1086/322575
– ident: e_1_3_4_41_1
  doi: 10.4161/hv.2.6.3432
– ident: e_1_3_4_80_1
– ident: e_1_3_4_37_1
  doi: 10.1016/j.vaccine.2004.06.017
– ident: e_1_3_4_19_1
  doi: 10.1067/mph.2003.42
– ident: e_1_3_4_20_1
  doi: 10.1097/00006454-200111001-00002
– ident: e_1_3_4_30_1
  doi: 10.1016/j.vaccine.2016.05.054
– ident: e_1_3_4_76_1
  doi: 10.1080/21645515.2020.1764826
– ident: e_1_3_4_49_1
  doi: 10.1097/INF.0b013e318212eb80
– ident: e_1_3_4_35_1
  doi: 10.1097/00006454-200209000-00014
– ident: e_1_3_4_43_1
  doi: 10.1542/peds.2005-2907
– ident: e_1_3_4_66_1
  doi: 10.1517/14712598.2013.774368
– ident: e_1_3_4_52_1
  doi: 10.1016/j.vaccine.2017.05.062
– ident: e_1_3_4_81_1
– ident: e_1_3_4_18_1
  doi: 10.15167/2421-4248/jpmh2020.61.3.1535
– ident: e_1_3_4_92_1
  doi: 10.1016/j.jval.2016.09.367
– ident: e_1_3_4_5_1
  doi: 10.1016/S0264-410X(98)00424-1
– ident: e_1_3_4_87_1
  doi: 10.1016/j.biologicals.2017.08.008
– ident: e_1_3_4_46_1
  doi: 10.1080/21645515.2016.1202388
– ident: e_1_3_4_86_1
  doi: 10.1097/00006454-200111001-00006
– ident: e_1_3_4_53_1
  doi: 10.3906/sag-1609-62
– ident: e_1_3_4_34_1
  doi: 10.1067/mpd.2000.107796
– ident: e_1_3_4_91_1
  doi: 10.1007/s10198-003-0216-z
– ident: e_1_3_4_63_1
  doi: 10.1016/j.vaccine.2021.08.086
– volume: 41
  start-page: 59
  year: 1988
  ident: e_1_3_4_7_1
  article-title: Expanded programme on immunization
  publication-title: World Health Stat Quarterly
  contributor:
    fullname: Keja K
– ident: e_1_3_4_25_1
  doi: 10.1111/1469-0691.12444
– ident: e_1_3_4_22_1
  doi: 10.1016/j.vaccine.2017.06.063
– ident: e_1_3_4_82_1
– ident: e_1_3_4_50_1
  doi: 10.4172/2157-7560.1000128
– ident: e_1_3_4_71_1
  doi: 10.1016/j.healthpol.2020.11.004
– ident: e_1_3_4_83_1
  doi: 10.1080/21645515.2021.1923345
– ident: e_1_3_4_79_1
– ident: e_1_3_4_55_1
  doi: 10.1097/INF.0000000000002109
– ident: e_1_3_4_4_1
– ident: e_1_3_4_77_1
  doi: 10.1016/j.vaccine.2023.08.046
– ident: e_1_3_4_85_1
  doi: 10.21101/cejph.a5543
– ident: e_1_3_4_51_1
  doi: 10.1097/INF.0000000000002231
– ident: e_1_3_4_9_1
  doi: 10.1097/00006454-199405000-00012
– ident: e_1_3_4_58_1
  doi: 10.1097/INF.0b013e318292f7b1
– ident: e_1_3_4_89_1
  doi: 10.1016/j.ijid.2014.03.1307
– ident: e_1_3_4_48_1
  doi: 10.1080/14760584.2018.1419070
– ident: e_1_3_4_60_1
  doi: 10.1542/peds.2014-4102
– ident: e_1_3_4_62_1
  doi: 10.1080/21645515.2019.1673119
– ident: e_1_3_4_65_1
  doi: 10.1586/erv.09.32
SSID ssj0000702466
Score 2.4004815
SecondaryResourceType review_article
Snippet The surge in recommended vaccinations for child's has spurred the development of combination vaccines, notably hexavalent vaccines, which provide multiple...
ABSTRACTThe surge in recommended vaccinations for child’s has spurred the development of combination vaccines, notably hexavalent vaccines, which provide...
SourceID doaj
proquest
crossref
pubmed
SourceType Open Website
Aggregation Database
Index Database
StartPage 2345493
SubjectTerms childhood immunization
combination vaccines
Hexavalant vaccines
Humans
Immunization Programs
Immunization Schedule
immunogenicity
Turkey
Vaccination
Vaccination Coverage
Vaccination Hesitancy - statistics & numerical data
vaccination strategies
vaccine safety
Vaccine-Preventable Diseases - prevention & control
Vaccines, Combined - administration & dosage
Vaccines, Combined - immunology
Title A worldwide overview for hexavalent vaccines and a glimpse into Turkiye's perspective
URI https://www.ncbi.nlm.nih.gov/pubmed/38780074
https://www.proquest.com/docview/3059257119
https://doaj.org/article/62b752f5c2d14292ac0d13074b7737f5
Volume 20
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3JTsMwELVQJSQuiJ2yyUhcQxPHietjQVQVEpxAcIvGS6AC0oq2LDd-g9_jS5hJUigHxIWrFSnOjP3mTcZ-w9iBNokBkdggV5EMpDM6MDammqv1DlxkVEwXhc_O096lPL1OrmdafdGZsEoeuDJcKxVGJSJPrHARtVYCGzrEXSWNUrHKK_XSUMwkUyUGK4w9ZaFSYD4QIC1Iptd32mGLxmgI00MhD0UsMUmKfwSmUr__d9JZBp_uElusWSPvVLNdZnO-WGHzVR_J11V21eGl8ulz33lOZzLpfz9HOspv_QvgWsLIwp_AUhF9xKFwHPjNff9hOPK8X4wH_GLyeNd_9R9v7yM-_L5-ucYuuycXx72g7pgQ2FiFY0QLkGBymbo0iSH1EfIv3GUGQtBIzEQIQAKCeSggdw6sDoWNQCOJAGeoJrnOGsWg8JuMa0xMANMHkRsjDSCkI6Qmeaq89khrbJMdTs2VDSthjCyq9Uan9s3Ivllt3yY7IqN-PUy61uUAejurvZ395e0m25-6JMN9QMUNKPxgMsoQtzTCTxTpJtuofPX1qrit2sSVtv5jCttsgT6rEnvcYY3x48TvIjEZm71yDX4CBeTasw
link.rule.ids 314,780,784,864,2102,27924,27925
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+worldwide+overview+for+hexavalent+vaccines+and+a+glimpse+into+Turkiye%27s+perspective&rft.jtitle=Human+vaccines+%26+immunotherapeutics&rft.au=%C3%96zen%2C+Metehan&rft.au=%C3%9Cn%C3%BCvar%2C+Emin&rft.au=Y%C4%B1ld%C4%B1r%C4%B1m%2C+Abdurrahman&rft.au=Akman%2C+Hakk%C4%B1&rft.date=2024-12-31&rft.eissn=2164-554X&rft.volume=20&rft.issue=1&rft.spage=2345493&rft_id=info:doi/10.1080%2F21645515.2024.2345493&rft_id=info%3Apmid%2F38780074&rft.externalDocID=38780074
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2164-5515&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2164-5515&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2164-5515&client=summon